TWI840378B - 二芳基吡啶衍生物之製造方法 - Google Patents

二芳基吡啶衍生物之製造方法 Download PDF

Info

Publication number
TWI840378B
TWI840378B TW108123125A TW108123125A TWI840378B TW I840378 B TWI840378 B TW I840378B TW 108123125 A TW108123125 A TW 108123125A TW 108123125 A TW108123125 A TW 108123125A TW I840378 B TWI840378 B TW I840378B
Authority
TW
Taiwan
Prior art keywords
formula
compound represented
added
solution
salt
Prior art date
Application number
TW108123125A
Other languages
English (en)
Chinese (zh)
Other versions
TW202005962A (zh
Inventor
安藝祐一
鳥山史彥
櫻井夏樹
龜田藍
小倉友和
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW202005962A publication Critical patent/TW202005962A/zh
Application granted granted Critical
Publication of TWI840378B publication Critical patent/TWI840378B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW108123125A 2018-07-04 2019-07-01 二芳基吡啶衍生物之製造方法 TWI840378B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-127197 2018-07-04
JP2018127197 2018-07-04

Publications (2)

Publication Number Publication Date
TW202005962A TW202005962A (zh) 2020-02-01
TWI840378B true TWI840378B (zh) 2024-05-01

Family

ID=69059540

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108123125A TWI840378B (zh) 2018-07-04 2019-07-01 二芳基吡啶衍生物之製造方法

Country Status (10)

Country Link
US (1) US11999724B2 (cg-RX-API-DMAC7.html)
EP (1) EP3819296B1 (cg-RX-API-DMAC7.html)
JP (2) JP7337058B2 (cg-RX-API-DMAC7.html)
CN (1) CN112368271A (cg-RX-API-DMAC7.html)
AU (1) AU2019299152A1 (cg-RX-API-DMAC7.html)
CA (1) CA3105328A1 (cg-RX-API-DMAC7.html)
ES (1) ES2925365T3 (cg-RX-API-DMAC7.html)
IL (1) IL279070B2 (cg-RX-API-DMAC7.html)
TW (1) TWI840378B (cg-RX-API-DMAC7.html)
WO (1) WO2020009132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023090337A1 (cg-RX-API-DMAC7.html) 2021-11-19 2023-05-25

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115280A1 (ja) * 2012-01-31 2013-08-08 第一三共株式会社 ピリドン誘導体
CN106604920A (zh) * 2014-07-07 2017-04-26 第三共株式会社 具有四氢吡喃基甲基的吡啶酮衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI796326B (zh) 2017-03-24 2023-03-21 日商第一三共股份有限公司 含有ａｘｌ抑制劑與ｅｇｆｒ酪胺酸激酶抑制藥的醫藥品及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115280A1 (ja) * 2012-01-31 2013-08-08 第一三共株式会社 ピリドン誘導体
CN106604920A (zh) * 2014-07-07 2017-04-26 第三共株式会社 具有四氢吡喃基甲基的吡啶酮衍生物

Also Published As

Publication number Publication date
TW202005962A (zh) 2020-02-01
US20210188823A1 (en) 2021-06-24
JP2023159297A (ja) 2023-10-31
ES2925365T3 (es) 2022-10-17
CA3105328A1 (en) 2020-01-09
IL279070B2 (en) 2024-05-01
JPWO2020009132A1 (ja) 2021-07-08
CN112368271A (zh) 2021-02-12
WO2020009132A1 (ja) 2020-01-09
EP3819296B1 (en) 2022-06-29
AU2019299152A1 (en) 2021-03-04
US11999724B2 (en) 2024-06-04
AU2019299152A2 (en) 2021-03-11
IL279070A (en) 2021-01-31
IL279070B1 (en) 2024-01-01
EP3819296A4 (en) 2021-06-09
EP3819296A1 (en) 2021-05-12
JP7337058B2 (ja) 2023-09-01

Similar Documents

Publication Publication Date Title
TWI753918B (zh) 作為ｊａｋ抑制劑的吡咯並嘧啶化合物的結晶
JP4996631B2 (ja) 無水結晶形態のＮ−［１−（２−エトキシエチル）−５−（Ｎ−エチル−Ｎ−メチルアミノ）−７−（４−メチルピリジン−２−イル−アミノ）−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−３−カルボニル］メタンスルホンアミド
CN102272124B (zh) 舒尼替尼苹果酸盐的新晶形
JP4142621B2 (ja) 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法
JP6832946B2 (ja) キナーゼ阻害剤およびその中間体の調製方法
CN110511158A (zh) 制备喹啉衍生物的方法
EA031059B1 (ru) Кристаллическая форма альфа дималеата афатиниба
CN111875607A (zh) 手性吡咯并嘧啶化合物的制备方法
KR20220016949A (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
AU2006216266A2 (en) Quinazoline derivative having tyrosine kinase inhibitory activity
CN110546147B (zh) 苯氧基喹唑啉化合物及其在治疗癌症中的用途
JP2021511299A (ja) 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
US20100087459A1 (en) Forms of lapatinib compounds and processes for the preparation thereof
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
TW202005962A (zh) 二芳基吡啶衍生物之製造方法
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
HK40047091A (en) Method for producing diarylpyridine derivatives
CN101223165B (zh) N-(3-甲氧基-5-甲基吡嗪-2-基)-2-(4-[1,3,4-二唑-2-基]苯基)吡啶-3-磺酰胺的乙醇胺盐
JP7492997B2 (ja) オラパリブの製造方法
WO2024077059A1 (en) Crystalline forms of an mk2 inhibitor
JP2010514685A (ja) アリール置換ピラゾールアミド化合物の結晶形
JP2013523613A (ja) ４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オン乳酸塩の水和物多形体の調製
HK1058932B (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees